The news of Oppenheimer maintaining an Outperform rating on Biogen and raising the price target from $350 to $360 is positive for the company. This indicates that the analyst has confidence in the company's performance and growth potential, which could lead to an increase in investor interest and a potential short-term increase in the stock price.